Chest pain drug could fight fetal

Chest pain drug could fight fetal fungal infection

London, June 9 (IANS) A drug, more commonly used in the treatment of angina — type of chest pain caused by reduced blood flow to heart — could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis, say researchers.

The compound fendiline hydrochloride could be used to stimulate a patient’s own white blood cells to fight the disease more effectively, instead of trying to use drugs that directly kill the fungus itself, the researchers found.

“Fungi are intrinsically more difficult to target than bacteria, because they are much more closely related, evolutionarily, to humans. Finding an essential pathway in a fungus that you could inhibit, which doesn’t exist in humans, is very difficult,” explained professor Robin May from University of Birmingham.

“Therefore the approach of stimulating your own immune system to kill the fungus, instead of killing it directly through treatment, is potentially more powerful,” he noted.

The study, published in the International Journal of Antimicrobial Agents, propose a role for calcium-channel blockers such as fendiline hydrochloride as potential inhibitors to the survival of Cryptococcus neoformans, the pathogen which causes cryptococcosis, and represent a promising strategy for future anticryptococcal drug design and therapy.

Cryptococcosis neoformans poses a major threat to immunocompromised patients and is a leading killer of HIV patients worldwide.

HIV/AIDS patients are particularly prone to cryptococcal infections, with an estimated overwhelming disease burden of about one million cases of cryptococcal meningitis per year.

The infection process begins with inhalation of infectious agents (spores or dessicated yeasts) resulting in a primary pulmonary infection, which can further disseminate to the central nervous system causing meningitis.

Cryptococci are particularly difficult to treat with antifungal agents due to their ability to manipulate and exist within the host’s immune response.

“Considering the poor status of current anticryptococcal drugs, new treatment options for cryptococcosis are much needed,” Rebecca Hall, also from the University of Birmingham, added.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of www.mangalorean.com or any employee thereof. www.mangalorean.com is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of www.mangalorean.com to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at  info@mangalorean.com. Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here